我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Clinical Utility of EsoGuard� as a Barrett's Esophagus Triage Test for On-duty Firefighters

Rachelle Hamblin, Victoria T. Lee, Brian J. deGuzman, Suman Verma, Lishan Aklog

Background: Firefighters have frequent exposure to smoke and compounds shown to increase the risk of esophageal neoplasia. However, many are unaware of their risk for Esophageal Adenocarcinoma (EAC) or the precursor condition Barrett's Esophagus (BE), and screening endoscopy can be difficult to accommodate with shift schedules. The EsoGuard®/EsoCheck® (EG/EC) solution includes a biomarker assay (EsoGuard®/EG) and a non-endoscopic esophageal cell collection device (EsoCheck®/EC), which can be utilized with efficiency and high tolerability as a triage test for BE/EAC.
Methods: This is a retrospective analysis of prospectively collected data on use of the EG/EC solution during two large health fairs for on-duty firefighters in San Antonio, TX, in January 2023.
Results: Firefighters were evaluated by physician volunteers; among those deemed at high risk for BE/EAC, 388 firefighters agreed to EG/EC testing. Over 99% (385/388) successfully provided EC cell samples for analysis, and the EG positivity rate was 7.27% (28/385). Among those who tested EG positive, 100% (28/28) were referred by the ordering physician for confirmatory upper endoscopy. No EG negative subjects were referred for additional testing.
Conclusion: In this initial experience, EG/EC proved to be a rapid, efficient, and well-tolerated test to triage on-duty firefighters at high risk of BE/EAC to endoscopy; EG results demonstrated strong physician decision impact.